Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

265 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial.
Bullock AJ, Schlechter BL, Fakih MG, Tsimberidou AM, Grossman JE, Gordon MS, Wilky BA, Pimentel A, Mahadevan D, Balmanoukian AS, Sanborn RE, Schwartz GK, Abou-Alfa GK, Segal NH, Bockorny B, Moser JC, Sharma S, Patel JM, Wu W, Chand D, Rosenthal K, Mednick G, Delepine C, Curiel TJ, Stebbing J, Lenz HJ, O'Day SJ, El-Khoueiry AB. Bullock AJ, et al. Among authors: abou alfa gk. Nat Med. 2024 Sep;30(9):2558-2567. doi: 10.1038/s41591-024-03083-7. Epub 2024 Jun 13. Nat Med. 2024. PMID: 38871975 Free PMC article. Clinical Trial.
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, Yarchoan M, De Toni EN, Furuse J, Kang YK, Galle PR, Rimassa L, Heurgué A, Tam VC, Van Dao T, Thungappa SC, Breder V, Ostapenko Y, Reig M, Makowsky M, Paskow MJ, Gupta C, Kurland JF, Negro A, Abou-Alfa GK; HIMALAYA investigators. Sangro B, et al. Ann Oncol. 2024 May;35(5):448-457. doi: 10.1016/j.annonc.2024.02.005. Epub 2024 Feb 19. Ann Oncol. 2024. PMID: 38382875 Free article. Clinical Trial.
An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202.
Vogel A, Sahai V, Hollebecque A, Vaccaro GM, Melisi D, Al Rajabi RM, Paulson AS, Borad MJ, Gallinson D, Murphy AG, Oh DY, Dotan E, Catenacci DV, Van Cutsem E, Lihou CF, Zhen H, Veronese ML, Abou-Alfa GK. Vogel A, et al. Among authors: abou alfa gk. ESMO Open. 2024 Jun;9(6):103488. doi: 10.1016/j.esmoop.2024.103488. Epub 2024 Jun 4. ESMO Open. 2024. PMID: 38838500 Free PMC article. Clinical Trial.
MEK Inhibitor-Associated Ocular Hypertension.
Collet DA, Canestraro J, Abou-Alfa GK, Abramson DH, Diamond EL, Francis JH. Collet DA, et al. Among authors: abou alfa gk. Ocul Oncol Pathol. 2024 Jun;10(2):98-102. doi: 10.1159/000535427. Epub 2023 Nov 30. Ocul Oncol Pathol. 2024. PMID: 38882021 Free PMC article.
Clinical and Genomic Characterization of ERBB2-Altered Gallbladder Cancer: Exploring Differences Between an American and a Chilean Cohort.
Mondaca S, Walch H, Sepúlveda S, Schultz N, Muñoz G, Yaqubie A, Macanas P, Pareja C, Garcia P, Chatila W, Nervi B, Li B, Harding JJ, Viviani P, Roa JC, Abou-Alfa GK. Mondaca S, et al. Among authors: abou alfa gk. JCO Glob Oncol. 2024 Oct;10:e2400090. doi: 10.1200/GO.24.00090. Epub 2024 Oct 10. JCO Glob Oncol. 2024. PMID: 39388662
Long term outcomes in patients with advanced intrahepatic cholangiocarcinoma treated with hepatic arterial infusion chemotherapy.
Cowzer D, Soares K, Walch H, Gönen M, Boucher TM, Do RKG, Harding JJ, Varghese AM, Reidy-Lagunes D, Saltz L, Connell LC, Abou-Alfa GK, Wei AC, Schultz N, Kingham TP, D'Angelica MI, Drebin JA, Balachandran V, Sanchez-Vega F, Kemeny NE, Jarnagin WR, Cercek A. Cowzer D, et al. Among authors: abou alfa gk. J Natl Cancer Inst. 2024 Sep 27:djae202. doi: 10.1093/jnci/djae202. Online ahead of print. J Natl Cancer Inst. 2024. PMID: 39331613
Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Lau G, Abou-Alfa GK, Cheng AL, Sukeepaisarnjaroen W, Van Dao T, Kang YK, Thungappa SC, Kudo M, Sangro B, Kelley RK, Furuse J, Park JW, Sunpaweravong P, Fasolo A, Yau T, Kawaoka T, Azevedo S, Reig M, Assenat E, Yarchoan M, He AR, Makowsky M, Gupta C, Negro A, Chan SL. Lau G, et al. Among authors: abou alfa gk. J Hepatol. 2024 Jul 31:S0168-8278(24)02424-3. doi: 10.1016/j.jhep.2024.07.017. Online ahead of print. J Hepatol. 2024. PMID: 39089633 Free article.
Has Management of Intrahepatic Cholangiocarcinoma Evolved with the Evidence? Trends and Practice Patterns from the National Cancer Database.
Schleimer LE, Kalvin HL, Ellis RJ, Kingham TP, Soares KC, D'Angelica MI, Balachandran VP, Drebin J, Cercek A, Abou-Alfa GK, O'Reilly EM, Harding JJ, Gönen M, Wei AC, Jarnagin WR. Schleimer LE, et al. Among authors: abou alfa gk. Ann Surg Oncol. 2024 Oct;31(10):6551-6563. doi: 10.1245/s10434-024-15724-9. Epub 2024 Jul 23. Ann Surg Oncol. 2024. PMID: 39042229
Clinicogenomic predictors of outcomes in patients with hepatocellular carcinoma treated with immunotherapy.
Cowzer D, Chou JF, Walch H, Keane F, Khalil D, Shia J, Do RKG, Yarmohammadi H, Erinjeri JP, El Dika I, Yaqubie A, Azhari H, Gambarin M, Hajj C, Crane C, Wei AC, Jarnagin W, Solit DB, Berger MF, O'Reilly EM, Schultz N, Chatila W, Capanu M, Abou-Alfa GK, Harding JJ. Cowzer D, et al. Among authors: abou alfa gk. Oncologist. 2024 Oct 3;29(10):894-903. doi: 10.1093/oncolo/oyae110. Oncologist. 2024. PMID: 38937977 Free PMC article.
265 results